Primary small cell neuroendocrine carcinoma of the urinary tract: a case report and literature review Authors: Xuanpeng Li, Bingke Chen, Fanfan Li, Xiaoming Wang, Xiangxiang Zhang, Yuping Zhao, Mao Zhang, Hengping Li Published: 2025 ABSTRACT AbstractBackgroundSmall cell neuroendocrine carcinoma of the urinary tract (SCC-UT) is an extremely rare genitourinary tumor, which is highly aggressive, prone to local or distant metastasis and has a very poor prognosis.Case presentationThis article reports a case of primary small cell neuroendocrine carcinoma of the ureter combined with invasive uroepithelial carcinoma. The patient underwent robot-assisted laparoscopic radical left nephrectomy, full-length ureteral resection, sleeve cystectomy, and pelvic lymph node dissection after exclusion of contraindications to surgery (preoperative assessment confirmed the absence of cardiopulmonary or coagulation abnormalities) and underwent 6 cycles of post operative etoposide/cisplatin adjuvant chemotherapy.ConclusionsThis case underscores the potential efficacy of multimodal therapy, combining robot-assisted surgical resection with adjuvant etoposide/cisplatin chemotherapy, in the management of primary small cell neuroendocrine carcinoma. The patient was detected no local or distant metastases, at 9 months postoperatively. However, the follow-up period of only 9 months is relatively short, which limits the long-term assessment of recurrence or survival. These findings provide a reference for clinical decision-making and underscore the potential benefits of multimodal treatment in this rare malignancy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12957-025-04109-1.Keywords: Small cell neuroendocrine carcinoma, Tumor of the urinary tract, Clinicopathological features, Immunohistochemistry Background Neuroendocrine carcinomas (NEC) are a relatively rare and highly aggressive group of malignant tumors which include carcinoid tumors, large cell carcinomas, and small cell carcinomas, usually occurring in the lungs and gastrointestinal tract. Small cell neuroendocrine carcinoma (SCNEC) is a subtype of neuroendocrine carcinoma, which is uncommon as a primary tumor in extrapulmonary organs, but has been reported in many sites, including the nasopharynx, cervix, kidneys, bladder, and prostate gland [1]. Small cell carcinoma is considered a high-grade neuroendocrine malignancy characterized by neuroendocrine differentiation [2]. Small cell neuroendocrine carcinoma of the urinary tract is an extremely rare pathologic type, with an overall prevalence of only 0.05% of neuroendocrine carcinomas, mainly in the bladder and prostate regions, and even rarer in the ureter [3]. Currently, there are four hypotheses regarding the tissue origin of small-cell neuroendocrine carcinoma of the urinary tract: (1) neuroendocrine differentiation of uroepithelial cells; (2) malignant transformation of intrinsic neuroendocrine cells of the urinary tract; (3) ectopic retention of neural crest cells in the ureter during embryonic development; (4) aberrant evolution of pluripotent stem cells into the uroepithelium or squamous epithelium during abnormal differentiation [4, 5]. Small cell neuroendocrine carcinomas are characterized by poor differentiation and high aggressiveness and are usually advanced at initial diagnosis, leading to a high metastatic potential and poor prognosis, with an average 5-year survival rate of approximately 8% [6]. In this study, we report a case of primary small cell neuroendocrine carcinoma in the urinary system (one case involved the ureter and was combined with invasive uroepithelial carcinoma). The relevant literature was reviewed and the clinical presentation, pathologic features, biological behavior, treatment, and prognostic outcomes of small cell carcinoma of the urinary tract were discussed. Case presentation In this study, we report a patient with small cell carcinoma of the urinary tract, a male, 62 years old, who presented to a local hospital with “intermittent left lower abdominal pain for 5 days”. Abdominal ultrasonography showed left hydronephrosis and dilatation of the upper part of the left ureter. Subsequently, an enhanced urologic CT scan showed a space-occupying lesion in the lower part of the left ureter with mild dilatation of its upper ureter and renal pelvis, suggesting a ureteral tumor. The patient was referred to the hospital where the author works. Post-admission review of urologic CT enhancement and 3D reconstruction showed a neoplastic lesion in the ventral segment of the left ureter and dilated ureteral effusion over the left kidney and space-occupying lesion in the ureter (Fig. 1). After exclusion of contraindications to surgery (preoperative assessment confirmed the absence of cardiopulmonary or coagulation abnormalities), robot-assisted laparoscopic radical left nephrectomy, full-length ureteral resection, sleeve cystectomy, and pelvic lymph node dissection were performed under general anesthesia. Preoperative CT urologic images of the patient. (The above images show CT-enhanced imaging of the urinary system at different times: A soft tissue density shadow with a range of 21 mm is seen in the lumen of the ventral segment of the left ureter, with uneven enhancement, more pronounced enhancement in the parenchymal phase, and reduced enhancement in the excretory phase, with dilated hydronephrosis of the ureter and the renal pelvis above it. A (arterial phase): The tumor showed marked enhancement with a filling defect. B (venous phase): The enhancement of the tumor was reduced compared with the arterial phase. C (excretory phase): Tumor enhancement was no longer observed. D: Sagittal view image) The patient was positioned in a modified right lateral decubitus position with elevation of the left flank to optimize exposure of the kidney and ureter, while also facilitating distal ureter dissection and bladder cuff excision. Port placement was as follows: a 10-mm camera trocar (A) was inserted 2 cm above the iliac crest; two 12-mm robotic working ports (B and C) were placed below the costal margin along the anterior and posterior axillary lines; and a 12-mm assistant port was positioned at the right rectus border for suction, clipping, and specimen handling. All robotic arms were docked through a retroperitoneal approach. Intraoperatively, the ureter was seen to be hard with no infiltration of surrounding tissue at the end, and no space-occupying lesions were found in the kidney or bladder.Standard robotic instruments were used, and the specimen was removed en bloc. A drain was placed in the iliac fossa and removed on postoperative day 3 when the drainage was minimal and serous in nature. Several technical challenges were encountered during distal ureter dissection and bladder cuff excision. The distal ureter was closely adherent to dense retroperitoneal tissue, requiring meticulous dissection to avoid injury to the iliac vessels and pelvic nerves. Bladder cuff excision necessitated complete removal of the left ureteral orifice while preserving the contralateral orifice and maintaining adequate bladder vascularity. Preservation of specimen integrity was essential to prevent tumor spillage. Pelvic lymph node dissection was technically demanding due to the limited anatomical space and proximity to the iliac vessels, requiring precise hemostasis and lymphatic control to reduce the risk of postoperative lymphorrhea. The patient tolerated the procedure well, and no intraoperative complications occurred. After the operation, mitomycin (40 mg) with saline (50 mL) was used to perform local perfusion chemotherapy for 20 min, and the drain was left in place after adequate rinsing, and the operation went smoothly. Postoperative pathological examination showed that the specimen was left kidney, ureter and part of bladder tissue (11 cm×6 cm×4 cm), and after dissection, a gray-white solid mass (2.0 cm×1.5 cm×1.0 cm) was found at the end of the ureter, which showed infiltrative growth on the cut surface and involved the whole wall of the tube, and the severed end of the ureter was not clearly demonstrated (Fig. 2). Immunohistochemical test results: CK7 (−, superficial migratory epithelium +), CK20 (−), p53 (+, mutation), p63 (−, superficial migratory epithelium +), Uroplakin III (Umbrella cells are scattered, +), AR (−), Gata-3 (−, superficial migratory epithelium +), PSA(−), Ki-67 (index:90%), Syn (+), PD-L1 (SP263) (−), Her-2 (SP263) (-), CgA (+), CD56 (+), (Fig. 3). Pathological diagnosis: small cell neuroendocrine carcinoma of the left ureter combined with invasive uroepithelial carcinoma with vascular invasion; no metastasis in the left iliac vascular lymph node. Postoperative recovery was good. Two months after the surgery, the patient received adjuvant chemotherapy (cisplatin and etoposide every 3 weeks for 6 cycles) (Table 1). The patient tolerated chemotherapy well, with only mild nausea and transient leukopenia (Grade 1) that resolved with supportive care. At 9 months, the patient’s KPS score was 90 (ECOG 0), indicating minor symptoms but full independence [7, 8]. Pathology specimens. (A: kidney tissue; B: ureteral tumor tissue; C: ureteral tissue; D: some bladder tissue) Pathologic results and immunohistochemical staining results. (The above images (A and B) are HE stains of different pathological features of tumor cells under electron microscope. Images (A) and (B) are magnified 40 times. The cells were diffusely distributed in sheets, stripes and nests, and some areas could be arranged in an adenoidal manner, showing a highly proliferative state. The tumor cells were small in size, round, ovoid or short spindle-shaped, with scanty cytoplasm, darkly stained and markedly anisotropic nuclei, coarsely granular nuclear chromatin, inconspicuous nucleoli, and nuclear schizophrenia with necrosis were common. Images (C-L) are stained for the SP×200 method. Images (C-L) are magnified 40 times. p53 (+, mutation); Gata-3 (−, superficial migratory epithelium +); (E) Uroplakin III (Umbrella cells are scattered, +); (F)CD56 (+); (G)CgA (+); (H) Ki-67 (index:90%); (I) Syn (+); (J) CK7 (−, superficial migratory epithelium +); (K)Her-2 (SP263) (-); (L)PD-L1 (SP263) (−) Table 1Hematologic parameters and adverse reactions during six cycles of etoposide/cisplatin chemotherapyCycleDateChemotherapy regimen (mg)WBC (×10⁹/L)Neutrophils (×10⁹/L)Lymphocytes (×10⁹/L)RBC (×10¹²/L)Hemoglobin (g/L)Platelets (×10⁹/L)Gastrointestinal reaction (nausea, vomiting, poor appetite)Allergic reaction1st2024-10-9Etoposide (125 mg) + Cisplatin (105 mg)4.43.240.864.07126104+++-2nd2024-11-1Etoposide (125 mg) + Cisplatin (105 mg)3.11.980.803.9912191++-3rd2024-11-22Etoposide (125 mg) + Cisplatin (105 mg)6.44.970.813.72117127++-4th2024-12-13Etoposide (125 mg) + Cisplatin (105 mg)4.33.010.883.81122136++-5th2025-1-4Etoposide (125 mg) + Cisplatin (105 mg)3.402.100.953.6311996+-6th2025-1-25Etoposide (125 mg) + Cisplatin (105 mg)2.901.610.923.37113112+-1 week later2025-2-2No5.403.411.474.60140180--Gastrointestinal reactions were graded semi-quantitatively as mild (+), moderate (++), or severe (+++); Allergic reaction (qualitative): “+” indicates positive; “−” indicates negativeWBC White blood cells, RBC Red blood cells Hematologic parameters and adverse reactions during six cycles of etoposide/cisplatin chemotherapy Gastrointestinal reactions were graded semi-quantitatively as mild (+), moderate (++), or severe (+++); Allergic reaction (qualitative): “+” indicates positive; “−” indicates negative WBC White blood cells, RBC Red blood cells Discussion and conclusion Neuroendocrine carcinoma of the urinary tract is a group of highly aggressive malignant tumors, mainly classified as small cell carcinoma and large cell carcinoma. Approximately 20% of neuroendocrine neoplasms may be linked to germline mutations (e.g. MEN1, DAXX, ATRX, TP53, RB1), genetic testing was not performed in this case [9, 10]. Small cell carcinoma of the urinary tract is a rare and highly aggressive malignancy, exhibiting poor biological behavior and an overall unfavorable clinical prognosis. It primarily occurs in the bladder and prostate, while small cell carcinoma of the ureter is extremely rare [11]. Small cell carcinoma of the urinary tract usually occurs in middle-aged and elderly men, and patients often lack specific clinical manifestations, with painless hematuria being the most common symptom, with an incidence of 60%–100% [12]. In addition, some patients may also develop paraneoplastic endocrine syndromes, including disorders of calcium or glucose metabolism and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Nevertheless, these syndromes are uncommon and occur far less frequently than in small cell lung carcinoma. Reported cases indicate that they are most often associated with small cell carcinoma of the bladder and prostate [13–16]. Diagnosis of small cell carcinoma of the urinary tract primarily relies on pathological examination, due to the lack distinctive features in both clinical presentation and imaging features, posing significant challenges in early diagnosis and treatment [17]. Although imaging studies can provide key information such as anatomical localization of the tumor, three-dimensional measurements of tumor size, degree of local infiltration, and assessment of distant metastasis, their diagnostic value remains significantly lower than that of pathological examinations [18] Small cell carcinomas are characterized microscopically by small tumor cells that are round to oval or spindle-shaped, with scant cytoplasm and indistinct cell borders; the nuclei are hyperchromatic, show marked pleomorphism, and have inconspicuous nucleoli; the cancer cells are densely packed, often arranged in nesting or trabecular patterns, and are accompanied by comedo-type necrosis; frequent mitotic figures are observed [19]. In addition, immunohistochemically, the neuroendocrine stains are usually positive (chromogranin A, synaptophysin, CD56, neuron-specific enolase) and it may show positivity for keratins such as cytokeratin (CK)7, epithelial membrane antigen, and pan-CK [20] In the present case, the diagnosis of small cell neuroendocrine carcinoma was confirmed by the presence of small round cells immunoreactive for synaptophysin, chromogranin A and CD56. The superficial urothelium exhibited invasive carcinoma positive for p53, Uroplakin III and GATA-3, confirming the coexistence of small cell neuroendocrine carcinoma and invasiv (Fig. 3). Small cell carcinoma of the urinary tract is clinically rare, and no standardized treatment protocol currently exists. Although this tumor type is sensitive to chemotherapy and radiotherapy, the overall prognosis remains poor. Therefore, multidisciplinary treatment combining surgical resection, chemotherapy, radiotherapy, and immunotherapy is often required. Radical nephroureterectomy combined with partial cystectomy is the preferred surgical approach for most patients and is often supplemented postoperatively with chemotherapy due to the tumor’s high heterogeneity and tendency for recurrence and metastasis [21]. Chemotherapy is typically administered in either a neoadjuvant or adjuvant setting. Platinum-based chemotherapy (etoposide/cisplatin) remains the mainstay of systemic treatment, with reported response rates of 60–80% and median survival around 12–20 months. Radiotherapy can improve local control in select cases but has limited effect on overall survival [22, 23]. For example, Farooq et al. [23] reported a case of small cell neuroendocrine carcinoma of the ureter with a favorable prognosis following comprehensive treatment. The patient underwent left laparoscopic nephroureterectomy, cystocele sleeve resection, and pelvic lymph node dissection, followed by two cycles of postoperative adjuvant chemotherapy with etoposide and cisplatin. Within five weeks after completing chemotherapy, the patient received pelvic three-dimensional conformal radiotherapy (a total dose of 50 Gy in 25 fractions). No signs of tumor recurrence or metastasis were observed during the 1-year follow-up. The principles of radiotherapy and chemotherapy as standard therapies for limited or extensive small cell lung cancer (SCLC) have been applied to the treatment of neuroendocrine carcinomas at extrapulmonary sites [24]. According to current research, radiotherapy is less commonly used in urothelial neuroendocrine carcinoma and is typically combined with postoperative adjuvant chemotherapy [21]. Beddok et al. [25] reported a case of recurrence four months after nephroureterectomy. The patient achieved 16 months of progression-free survival following radiotherapy, after showing a partial response to adjuvant chemotherapy with a carboplatin and etoposide regimen. This case suggests that radiotherapy may serve as a complementary treatment option for patients who achieve partial remission with chemotherapy. The median overall survival for patients with small cell carcinoma of the urinary tract who received surgery followed by adjuvant radiotherapy was 15 months, while those with metastatic disease had a median survival of less than 2 months [26]. Therefore, in-depth investigations into the pathogenesis of urothelial neuroendocrine carcinoma, the development of novel targeted therapies, the conduct of multicenter clinical trials, and the establishment of a multimodal comprehensive treatment strategy are of great clinical significance for improving quality of life and extending patient survival. In this case, the patient had a locally early-stage tumor (T2N0M0) with highly aggressive behavior and underwent robot-assisted radical nephroureterectomy combined with bladder cuff excision. Based on the efficacy of etoposide/cisplatin chemotherapy in extrapulmonary small cell carcinoma, this regimen was chosen as adjuvant therapy. Given the clear surgical margins and absence of lymph node metastasis, radiotherapy was considered unnecessary. In addition, immunotherapy has shown great potential in the treatment of SCLC. Mansfield et al.16 demonstrated that the addition of atezolizumab to a carboplatin and etoposide regimen significantly improved both progression-free survival and overall survival in patients with extensive-stage SCLC. However, clinical application of this immunotherapy regimen in urothelial small cell neuroendocrine carcinoma has not been reported to date. In this case, intraoperative intravesical chemotherapy with mitomycin C (MMC) was administered to reduce the risk of tumor seeding and urinary tract recurrence. However, this approach is not a standard oncological procedure but rather a preventive measure adopted at the surgeon’s discretion [27] Small cell carcinoma of the urinary tract is a distinct pathological subtype of urologic tumors, characterized by high aggressiveness and a very poor prognosis, with an average survival of only a few months. Treatment is tailored to individual patient characteristics, with surgical resection combined with adjuvant chemotherapy being the most commonly chosen approach. The present case report is consistent with previously published retrospective data, which demonstrated long-term survival after six cycles of adjuvant chemotherapy following surgical resection of small cell carcinoma of the urinary tract. However, this study has certain limitations, including a short follow-up period, the single-case nature of the report, and the lack of genetic analysis. In addition, future development of effective systemic therapies, particularly targeted treatments, is anticipated. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements Not applicable. Abbreviations Computed tomography Authors’ contributions Xuanpeng Li and Bingke Chen: Conceptualization, Investigation, Methodology, Writing–original draft. Mao Zhang and Xiangxiang Zhang: Resources, Supervision, Validation. Fanfan Li, Xiaoming Wang and Yuping Zhao: Investigation, Supervision. Hengping Li: Funding acquisition, Resources, Validation, Writing – review & editing. Funding This research was funded by Gansu Provincial Science and Technology Plan (Joint Scientific Research Fund) Project (24JRA892); Gansu Provincial Hospital Internal Scientific Research Fund Project (23GSSYF-20); Gansu Provincial Hospital Internal Scientific Research Fund Project (2024KYQDJ-A-10); The APC for this study was funded by Gansu Provincial Science and Technology Plan (Joint Scientific Research Fund) Project (24JRA892). Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval The case report was exempt from ethical approval by the Ethics Committee of Gansu Provincial Hospital, because we have obtained informed consent from the patient, which is not the design of the clinical trial. We have obtained informed consent from the patient and told the patient not at any risk to him. On the basis of full patient understanding and consent, informed consent was signed and consent was provided with the medical information to be used for scientific research and publications. Consent for publication Written informed consent was obtained from the patient for publication of this case report, and the accompanying images. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement No datasets were generated or analysed during the current study.